Caris Life Sciences Selects Illumina, Inc. (ILMN)'s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling Service
11/7/2012 9:40:45 AM
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris’ evidence-based molecular profiling service. The MiSeq system will be deployed to enable rapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illumina’s amplicon-based assay. Caris Life Sciences’ molecular profiling service offers comprehensive tumor biomarker analyses coupled with an extensive clinical literature review, which matches potential therapies to patient-specific biomarker information. Using a wide array of the most clinically relevant technologies available, this service continually evolves with the emerging science to help oncologists personalize care for cancer patients. The addition of next-generation sequencing to Caris’ molecular profiling service represents the next step in the natural evolution of this cutting-edge offering.